Gene and cell therapy of human genetic diseases: Recent advances and future directions

被引:2
作者
Cetin, Busra [1 ]
Erendor, Fulya [1 ]
Eksi, Yunus E. [1 ]
Sanlioglu, Ahter D. [1 ]
Sanlioglu, Salih [1 ]
机构
[1] Akdeniz Univ, Fac Med, Dept Gene & Cell Therapy, Antalya, Turkiye
关键词
cell therapy; CRISPR/Cas9; gene editing; gene therapy; viral vectors; DRUG; APPROVAL;
D O I
10.1111/jcmm.70056
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Disruptions in normal development and the emergence of health conditions often result from the malfunction of vital genes in the human body. Decades of scientific research have focused on techniques to modify or substitute defective genes with healthy alternatives, marking a new era in disease treatment, prevention and cure. Recent strides in science and technology have reshaped our understanding of disorders, medication development and treatment recommendations, with human gene and cell therapy at the forefront of this transformative shift. Its primary objective is the modification of genes or adjustment of cell behaviour for therapeutic purposes. In this review, we focus on the latest advances in gene and cell therapy for treating human genetic diseases, with a particular emphasis on FDA and EMA-approved therapies and the evolving landscape of genome editing. We examine the current state of innovative gene editing technologies, particularly the CRISPR-Cas systems. As we explore the progress, ethical considerations and prospects of these innovations, we gain insight into their potential to revolutionize the treatment of genetic diseases, along with a discussion of the challenges associated with their regulatory pathways. This review traces the origins and evolution of these therapies, from conceptual ideas to practical clinical applications, marking a significant milestone in the field of medical science.
引用
收藏
页数:15
相关论文
共 91 条
[1]   Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products [J].
Aiuti, Alessandro ;
Roncarolo, Maria Grazia ;
Naldini, Luigi .
EMBO MOLECULAR MEDICINE, 2017, 9 (06) :737-740
[2]   Novel genetic therapeutic approaches for modulating the severity of β-thalassemia (Review) [J].
Amjad, Fareeha ;
Fatima, Tamseel ;
Fayyaz, Tuba ;
Khan, Muhammad Aslam ;
Qadeer, Muhammad Imran .
BIOMEDICAL REPORTS, 2020, 13 (05) :1-11
[3]   Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma [J].
Andtbacka, Robert H. I. ;
Kaufman, Howard L. ;
Collichio, Frances ;
Amatruda, Thomas ;
Senzer, Neil ;
Chesney, Jason ;
Delman, Keith A. ;
Spitler, Lynn E. ;
Puzanov, Igor ;
Agarwala, Sanjiv S. ;
Milhem, Mohammed ;
Cranmer, Lee ;
Curti, Brendan ;
Lewis, Karl ;
Ross, Merrick ;
Guthrie, Troy ;
Linette, Gerald P. ;
Daniels, Gregory A. ;
Harrington, Kevin ;
Middleton, Mark R. ;
Miller, Wilson H., Jr. ;
Zager, Jonathan S. ;
Ye, Yining ;
Yao, Bin ;
Li, Ai ;
Doleman, Susan ;
VanderWalde, Ari ;
Gansert, Jennifer ;
Coffin, Robert S. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) :2780-U98
[4]  
[Anonymous], Luxturna 2017
[5]  
[Anonymous], 2022, What is Kymriah?
[6]  
[Anonymous], 2021, Spinal Muscular Atrophy (SMA)
[7]  
[Anonymous], 2020, MEDLINEPLUS
[8]  
[Anonymous], 2023, Gene therapy clinical trials worldwide
[9]  
[Anonymous], 2021, ZYNTEGLO clinical trials overview
[10]  
[Anonymous], 2017, FDA approves personalized cellular therapy for advanced leukemia